La Jolla Pharmaceutical Co. (NASDAQ:LJPC) shares traded up 3.2% during mid-day trading on Monday . The stock traded as high as $16.47 and last traded at $16.39, with a volume of 57,719 shares. The stock had previously closed at $15.88.

Several research analysts have recently issued reports on the stock. Jefferies Group reiterated a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 8th. Zacks Investment Research cut shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, June 15th. SunTrust Banks Inc. initiated coverage on shares of La Jolla Pharmaceutical in a report on Wednesday, June 22nd. They set a “buy” rating and a $30.00 price objective for the company. Finally, Lake Street Capital initiated coverage on shares of La Jolla Pharmaceutical in a report on Tuesday, May 24th. They set a “buy” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. La Jolla Pharmaceutical currently has an average rating of “Buy” and an average target price of $39.50.

The firm’s market capitalization is $298.82 million. The company’s 50 day moving average price is $16.74 and its 200 day moving average price is $17.76.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.22. Equities analysts predict that La Jolla Pharmaceutical Co. will post ($3.99) EPS for the current year.

An institutional investor recently raised its position in La Jolla Pharmaceutical stock. P.A.W. Capital Corp raised its position in shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical accounts for 1.5% of P.A.W. Capital Corp’s portfolio, making the stock its 28th largest position. P.A.W. Capital Corp owned 0.28% of La Jolla Pharmaceutical worth $1,361,000 at the end of the most recent quarter.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.